title: Drugmakers struggle with Indian patents.
abstract: Pharmaceutical companies continue their legal battles for intellectual property protection for their drugs in India after the country's patent office revoked Pfizer's local patent for Sutent (sunitinib malate).
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D001549:Benzamides / Q000191:economics; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D000068877:Imatinib Mesylate; D007194:India; D007211:Indoles / Q000191:economics; D009536:Niacinamide / Q000031:analogs & derivatives / Q000191:economics; D010330:Patents as Topic; D010671:Phenylurea Compounds / Q000191:economics; D010879:Piperazines / Q000191:economics; D011743:Pyrimidines / Q000191:economics; D011758:Pyrroles / Q000191:economics; D000077157:Sorafenib; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D007211:Indoles; D010671:Phenylurea Compounds; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D009536:Niacinamide; D000068877:Imatinib Mesylate; D000077157:Sorafenib; D000077210:Sunitinib